IBIO
Ibio Inc
NASDAQ · Biotechnology
$2.42
+0.27 (+12.56%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 20.82M | 19.24M | 18.65M |
| Net Income | -2,950,674 | -3,136,016 | -2,526,921 |
| EPS | — | — | — |
| Profit Margin | -14.2% | -16.3% | -13.6% |
| Rev Growth | +9.7% | -5.9% | +5.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 18.88M | 23.44M | 21.95M |
| Total Equity | 33.91M | 30.82M | 33.89M |
| D/E Ratio | 0.56 | 0.76 | 0.65 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -4,486,253 | -4,591,050 | -4,236,243 |
| Free Cash Flow | -3,503,805 | -2,958,449 | -2,128,422 |